发明名称 |
Assays for detecting neutralizing autoantibodies to biologic therapy |
摘要 |
The present invention provides assays for detecting and measuring the presence or level of neutralizing and non-neutralizing autoantibodies to biologics such as anti-TNFα drug therapeutics in a sample. The present invention is useful for monitoring the formation of neutralizing and/or non-neutralizing anti-drug antibodies over time while a subject is on biologic therapy. The present invention is also useful for predicting and/or determining the cross-reactivity of neutralizing anti-drug antibodies in a subject's sample with alternative biologic therapies. As such, the present invention provides information for guiding treatment decisions for those subjects receiving therapy with a biologic agent and improves the accuracy of optimizing therapy, reducing toxicity, and/or monitoring the efficacy of therapeutic treatment to biologic therapy. |
申请公布号 |
US9465027(B2) |
申请公布日期 |
2016.10.11 |
申请号 |
US201314144261 |
申请日期 |
2013.12.30 |
申请人 |
Nestec S.A. |
发明人 |
Hauenstein Scott;Ohrmund Linda;Singh Sharat;Wang Shui Long |
分类号 |
G01N33/53;G01N33/564;G01N33/68 |
主分类号 |
G01N33/53 |
代理机构 |
Kilpatrick Townsend & Stockton LLP |
代理人 |
Kilpatrick Townsend & Stockton LLP |
主权项 |
1. A method for measuring a percent of a neutralizing form of an autoantibody to an anti-TNFα drug in a sample, the method comprising:
(a) contacting the sample with a labeled anti-TNFα drug and a labeled TNFα to form:
(i) a first labeled complex of the labeled anti-TNFα drug and the autoantibody; and/or(ii) a second labeled complex of the labeled anti-TNFα drug, the labeled TNFα, and the autoantibody; (b) subjecting the first labeled complex and/or the second labeled complex to size exclusion chromatography to separate them from free labeled TNFα, free labeled anti-TNFα drug, and/or a complex of labeled anti-TNFα drug and labeled TNFα; (c) measuring an area under the curve (AUC) of free labeled TNFα in the sample (Free labeled TNFαAUC of the sample) after size exclusion chromatography; and (d) measuring the percent of a neutralizing form of the autoantibody by comparing the AUC of free labeled TNFα measured in step (c) to an AUC of free labeled TNFα in a first control sample (Free labeled TNFαAUC of the first control sample) and an AUC of free labeled TNFα in a second control sample (Free labeled TNFαAUC of the second control sample) using the equation:
((Free labeled TNFαAUC of the sample−Free labeled TNFαAUC of the first control sample)/Free labeled TNFαAUC of the second control sample)*100,wherein the first control sample is a reference sample that is normal human serum to which labeled TNFα and labeled anti-TNFα drug has been added, and the second control sample is a reference sample that is normal human serum to which only labeled TNFα has been added. |
地址 |
Vevey CH |